Mustang Bio financials
$0.4796−5.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.2M | -$1.1M | -$670.0K | -$624.0K | -$885.0K | -$253.0K | -$1.0M | -$1.5M | -$8.5M | -$5.2M | -$8.9M | -$11.7M |
| Net income | -$1.1M | -$955.0K | -$538.0K | -$468.0K | -$762.0K | -$153.0K | -$952.0K | -$1.4M | -$8.2M | -$5.2M | -$8.6M | -$10.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.16 | $-0.14 | $-0.08 | $-0.07 | $-0.19 | $-0.05 | $-0.90 | $-1.96 | $-18.36 | $-24.81 | $-42.98 | $-61.50 |
| EBITDA | -$1.2M | -$1.1M | -$670.0K | -$624.0K | -$885.0K | -$219.0K | $77.0K | -$1.4M | -$5.6M | -$4.9M | -$8.0M | -$11.4M |
| Operating cash flow | -$967.0K | -$1.0M | -$1.7M | -$818.0K | -$1.3M | -$1.4M | -$2.0M | -$1.8M | -$2.3M | -$5.3M | -$7.3M | -$12.0M |
| Free cash flow | -$967.0K | -$1.0M | -$1.7M | -$818.0K | -$1.3M | -$1.4M | -$2.0M | -$1.8M | -$2.3M | -$5.3M | -$7.3M | -$12.0M |
| Diluted shares | 6.7M | 6.7M | 6.5M | 6.2M | 4.0M | 2.9M | 1.1M | 0.7M | 0.4M | 0.2M | 0.2M | 0.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.2M | $16.3M | $17.3M | $19.0M | $12.7M | $14.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $15.6M | $16.6M | $17.6M | $19.4M | $13.0M | $14.9M |
| Total liabilities | $8.1M | $8.0M | $8.1M | $9.6M | $10.2M | $11.3M |
| Shareholders' equity | $7.5M | $8.6M | $9.5M | $9.8M | $2.9M | $3.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology